Advanes of Driving Genes in Bone Metastases from Lung Cancer

The skeleton is a common hematogenous metastasis site in lung cancer. The incidence of bone metastases in lung cancer patients is 30%-40%. It mainly occurs in the spine and the proximal trunk, including the spine, femur, ribs and sternum. The median overall survival time of these patients is 6-10 months, and the 1-year survival rate is 40%-50%. Exploring the molecular mechanism of bone metastasis has important guiding significance for the treatment. Some studies showed that driving genes in primary lesion and bone metastases sites are heterogeneous. However, it is still uncertain that the role of lung cancer driving genes in bone metastasis and their impact on bone microenvironment. This paper reviews the recent advances of molecular mechanisms of bone metastasis from lung cancer, focuses on the role of common driving genes in lung cancer bone metastasis and its effect on bone microenvironment.